NFKB1 and primary cutaneous T-cell non-Hodgkin lymphoma: Vorinostat and Romidepsin are acetylation inhibitors that downregulate activity of NF-κB in CTCL and are FDA-approved agents for the treatment of CTCL [18, 82, 83].